MX2020013320A - Inhibidores de ectonucleotidasa y métodos de uso de los mismos. - Google Patents

Inhibidores de ectonucleotidasa y métodos de uso de los mismos.

Info

Publication number
MX2020013320A
MX2020013320A MX2020013320A MX2020013320A MX2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A
Authority
MX
Mexico
Prior art keywords
methods
ectonucleotidase inhibitors
ectonucleotidase
inhibitors
heterocyclic compounds
Prior art date
Application number
MX2020013320A
Other languages
English (en)
Inventor
Jim Li
Lijing Chen
Roland Joseph Billedeau
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MX2020013320A publication Critical patent/MX2020013320A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a nuevos compuestos heterocíclicos y preparaciones farmacéuticas de los mismos. La invención se refiere además a métodos para tratar o prevenir el cáncer usando los nuevos compuestos heterocíclicos de la invención.
MX2020013320A 2018-06-21 2019-06-20 Inhibidores de ectonucleotidasa y métodos de uso de los mismos. MX2020013320A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688225P 2018-06-21 2018-06-21
US201962827505P 2019-04-01 2019-04-01
PCT/US2019/038245 WO2019246403A1 (en) 2018-06-21 2019-06-20 Ectonucleotidase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2020013320A true MX2020013320A (es) 2021-02-22

Family

ID=68981317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013320A MX2020013320A (es) 2018-06-21 2019-06-20 Inhibidores de ectonucleotidasa y métodos de uso de los mismos.

Country Status (16)

Country Link
US (3) US11078228B2 (es)
EP (1) EP3810617A4 (es)
JP (1) JP2021529172A (es)
KR (1) KR20210024561A (es)
CN (1) CN112888696B (es)
AU (1) AU2019288495B2 (es)
BR (1) BR112020025132B1 (es)
CA (1) CA3104088A1 (es)
CL (1) CL2020003339A1 (es)
CO (1) CO2021000049A2 (es)
IL (1) IL279475A (es)
MX (1) MX2020013320A (es)
PH (1) PH12020552214A1 (es)
SG (1) SG11202012001YA (es)
TW (1) TW202010750A (es)
WO (1) WO2019246403A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119284A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
EP3787635A4 (en) 2018-04-30 2022-03-02 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
CN114008048A (zh) * 2019-06-20 2022-02-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
MX2022005256A (es) 2019-10-30 2022-08-25 Oric Pharmaceuticals Inc Inhibidores de cd73.
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN115873049B (zh) * 2023-02-13 2023-05-02 北京先通国际医药科技股份有限公司 腺苷的制备方法及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008669B1 (ko) 1991-04-24 1996-06-28 야마사 쇼오유 가부시끼가이샤 1-β-D-아라비노푸라노실-(E)-5-(2-할로게노비닐) 우라실 유도체
WO1994010128A1 (en) 1992-11-02 1994-05-11 Affymax Technologies N.V. Novel photoreactive protecting groups
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
WO2008011406A2 (en) * 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
US8603998B2 (en) 2007-11-07 2013-12-10 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
CA2684017A1 (en) 2009-10-22 2011-04-22 Universite Laval Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2590958B1 (en) 2010-07-08 2015-08-26 Life Technologies Corporation In situ chemiluminescent substrates and assays
CN102311472B (zh) 2010-07-09 2014-09-03 神隆(昆山)生化科技有限公司 2-氯-9-(2’-脱氧-2’-氟-β-D-***呋喃糖基)-腺嘌呤的制备
EP2705031B1 (en) 2011-05-03 2018-04-11 Life Technologies Corporation Flash and glow 1,2-dioxetanes
ES2713566T3 (es) * 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US10068577B2 (en) * 2014-04-25 2018-09-04 Dolby Laboratories Licensing Corporation Audio segmentation based on spatial metadata
JP6657182B2 (ja) 2014-04-25 2020-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
EP3322713B1 (en) * 2015-12-03 2021-01-20 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3510040A4 (en) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
WO2018119284A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) * 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN109503587B (zh) * 2017-09-14 2022-01-11 辽宁利锋科技开发有限公司 双杂环三氮唑核苷类似物的抗肿瘤作用与应用
US11377469B2 (en) * 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
EP3787635A4 (en) * 2018-04-30 2022-03-02 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
EP3810109A4 (en) * 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. COMPOSITIONS AND METHODS FOR INHIBITING CD73
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
CN114008048A (zh) 2019-06-20 2022-02-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法

Also Published As

Publication number Publication date
CO2021000049A2 (es) 2021-04-19
TW202010750A (zh) 2020-03-16
WO2019246403A1 (en) 2019-12-26
US20240132533A1 (en) 2024-04-25
US20190389899A1 (en) 2019-12-26
BR112020025132B1 (pt) 2023-10-10
EP3810617A4 (en) 2022-06-29
SG11202012001YA (en) 2021-01-28
JP2021529172A (ja) 2021-10-28
CL2020003339A1 (es) 2021-06-25
AU2019288495B2 (en) 2024-02-08
EP3810617A1 (en) 2021-04-28
US11078228B2 (en) 2021-08-03
AU2019288495A1 (en) 2021-01-28
BR112020025132A2 (pt) 2021-03-23
KR20210024561A (ko) 2021-03-05
US20230022922A1 (en) 2023-01-26
CN112888696A (zh) 2021-06-01
US11858957B2 (en) 2024-01-02
IL279475A (en) 2021-01-31
CN112888696B (zh) 2024-04-16
PH12020552214A1 (en) 2021-08-16
CA3104088A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
ZA202007007B (en) Mcl-1 inhibitors
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2021008533A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MY201291A (en) Aminothiazole compounds as protein kinase inhibitors
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
MX2021011699A (es) Derivados de quinolina y su uso para el tratamiento del cancer.
MX2020010156A (es) Inhibidores de la secrecion de proteina cdp.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.